<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>health benefits &#8211; 21 Delivery</title>
	<atom:link href="https://www.21delivery.com/tag/health-benefits/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.21delivery.com</link>
	<description></description>
	<lastBuildDate>Tue, 16 Dec 2014 01:29:04 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.7.2</generator>
	<item>
		<title>NIDA Research on the Therapeutic Benefits of Cannabis and Cannabinoids</title>
		<link>https://www.21delivery.com/nida-research-on-the-therapeutic-benefits-of-cannabis-and-cannabinoids/</link>
					<comments>https://www.21delivery.com/nida-research-on-the-therapeutic-benefits-of-cannabis-and-cannabinoids/#respond</comments>
		
		<dc:creator><![CDATA[The Early Man]]></dc:creator>
		<pubDate>Tue, 16 Dec 2014 01:29:04 +0000</pubDate>
				<category><![CDATA[Cannabis-Blog]]></category>
		<category><![CDATA[health benefits]]></category>
		<guid isPermaLink="false">http://ohanadelivery.com/?p=421</guid>

					<description><![CDATA[Currently there is considerable interest in the possible therapeutic uses of marijuana (see our fact sheet, “Is Marijuana Medicine?”). As of January 31, 2014, there were 28 active grants related to this topic, funded by NIDA, in 6 different disease categories (see table, below). Therapeutic research is defined here as projects that include (as at [&#8230;]]]></description>
										<content:encoded><![CDATA[<p class="">Currently there is considerable interest in the possible therapeutic uses of marijuana (see our fact sheet, “<a href="http://www.drugabuse.gov/publications/drugfacts/marijuana-medicine">Is Marijuana Medicine?</a>”). As of January 31, 2014, there were 28 active grants related to this topic, funded by NIDA, in 6 different disease categories (see table, below). Therapeutic research is defined here as projects that include (as at least one of their specific aims) investigation of the potential medical benefit of the marijuana plant (<em>Cannabis sativa</em>) or its constituent<em>cannabinoid</em> chemicals in human or animal models of disease.</p>
<p>Most of these research projects are examining the medical benefits of individual cannabinoid chemicals derived from or related to those in the marijuana plant, not the plant itself, although a few use unprocessed plant material. Individual cannabinoid chemicals may be isolated and purified from the marijuana plant or synthesized in the laboratory, or they may be naturally occurring (endogenous) cannabinoids found in the body and modified using other, non-cannabinoid chemicals.</p>
<p>Specifically, cannabinoids are classified here as:</p>
<ul>
<li><strong>Plant</strong>  – plant leaves, flowers, stems, and seeds collected from the <em>Cannabis sativa</em> plant and ingested in some form (cigarettes, vapor); also known as phytocannabinoids.</li>
<li><strong>Endogenous</strong> – cannabinoids made by the body: <em>N</em>-arachidonoylethanolamine or anandamide (AE) or 2-arachidonoylglycerol ( 2-AG).  AE and 2-AG activity is manipulated by inhibiting their corresponding hydrolases FAAH or MAGL, preventing their degradation.</li>
<li><strong>Purified</strong> – naturally occurring cannabinoids purified from plant sources:  Cannabidiol (CBD), D9-tetrahydrocannabinol (THC), and Sativex (mixture of THC and CBD).</li>
<li><strong>Synthetic</strong> –cannabinoids synthesized in a laboratory: CB1 agonists (CPP-55, ACPA), CB2 agonists (JWH-133, NMP7, AM1241), CB1/CB2 nonselective agonist (CP55,940), Ajulemic Acid (AJA), Nabilone, Dronabinol, and several other proprietary chemicals in development as potential cannabinoid agonists and antagonists for therapeutic use.</li>
</ul>
<h2>How the Portfolio Analysis Was Conducted:</h2>
<ul>
<li>An internal NIH database (QVR) was searched on January 31, 2014 using the following:  TEXT word string “cannabinoid OR cannabis OR marijuana”; active grants</li>
<li>317 grants were manually screened to identify studies in which at least one specific aim included a therapeutic focus.</li>
<li>28 projects were identified (25 projects + 3 supplements) and are listed in the table below.</li>
</ul>
<p class="highlight">In the table, projects are divided into six disease categories:<em>autoimmune diseases</em>, <em>inflammation</em>, <em>pain</em>, <em>psychiatric disorders</em>, <em>seizures</em>, and <em>substance use disorders </em>(<em>SUD</em>s). Clicking on individual project titles leads to their descriptions in NIH RePorter. Also listed are the cannabinoid substances being examined and, except in cases when the whole plant was used, whether the studied chemicals are purified from the plant, synthetic, or endogenous; and whether the project uses human or animal subjects.</p>
<table class="full">
<caption><span class="title">Autoimmune disease</span></caption>
<thead>
<tr class="odd">
<th class="45" scope="col">Project Title</th>
<th class="35" scope="col">Cannabinoid</th>
<th class="30" scope="col">Study Model</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td scope="row"><a href="http://projectreporter.nih.gov/project_info_description.cfm?aid=8279206">TRANSDERMAL DELIVERY OF 2-ARACHIDONOYL GLYCEROL (2-AG) FOR THE TREATMENT OF ARTHR</a></td>
<td>Endogenous (2-AG)</td>
<td>Animal</td>
</tr>
</tbody>
</table>
<table class="full">
<caption><span class="title">Inflammation</span></caption>
<thead>
<tr class="odd">
<th class="45" scope="col">Project Title</th>
<th class="35" scope="col">Cannabinoid</th>
<th class="30" scope="col">Study Model</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td scope="row"><a href="http://projectreporter.nih.gov/project_info_description.cfm?aid=8433411">CANNABINOID EPIGENOMIC AND MIRNA MECHANISMS IMPACT HIV/SIV DISEASE PROGRESSION</a></td>
<td>Purified (THC)</td>
<td>Animal</td>
</tr>
<tr class="even">
<td scope="row"><a href="http://projectreporter.nih.gov/project_info_description.cfm?aid=8426161">CANNABINOID MODULATION OF MICROGLIAL RESPONSE TO THE HIV PROTEIN TAT</a></td>
<td>Purified and Synthetic (THC and CP55940)</td>
<td>Cell culture and animal models</td>
</tr>
</tbody>
</table>
<table class="full">
<caption><span class="title">Pain</span></caption>
<thead>
<tr class="odd">
<th class="45" scope="col">Project Title</th>
<th class="35" scope="col">Cannabinoid</th>
<th class="30" scope="col">Study Model</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td scope="row"><a href="http://projectreporter.nih.gov/project_info_description.cfm?aid=8484810">BEHAVIORAL ECONOMIC ANALYSIS OF MEDICAL MARIJUANA USE IN HIV+ PATIENTS</a></td>
<td>Plant (cannabis cigarettes)</td>
<td>Human</td>
</tr>
<tr class="even">
<td scope="row"><a href="http://projectreporter.nih.gov/project_info_description.cfm?aid=8425103">CANNABINOID MODULATION OF HYPERALGESIA</a></td>
<td>Endogenous (AE and 2-AG via URB597 FAAH inhibitor and JZL184 MAGL inhibitor)</td>
<td>Animal</td>
</tr>
<tr class="odd">
<td scope="row"><a href="http://projectreporter.nih.gov/project_info_description.cfm?aid=8591282">CANNABINOID RECEPTOR AGONISTS FOR TREATMENT OF CHRONIC PAIN</a></td>
<td>Synthetic (CB2 agonist, proprietary)</td>
<td>Animal</td>
</tr>
<tr class="even">
<td scope="row"><a href="http://projectreporter.nih.gov/project_info_description.cfm?aid=8531525">OPTIMIZING ANALGESIA BY EXPLOITING CB2 AGONIST FUNCTIONAL SELECTIVITY</a></td>
<td>Synthetic (CB2 agonists, proprietary)</td>
<td>Animal</td>
</tr>
<tr class="odd">
<td scope="row"><a href="http://projectreporter.nih.gov/project_info_description.cfm?aid=8455641">PERIPHERAL FAAH AS A TARGET FOR NOVEL ANALGESICS</a></td>
<td>Endogenous (AE via FAAH inhibitor (URB937))</td>
<td>Animal</td>
</tr>
<tr class="even">
<td scope="row"><a href="http://projectreporter.nih.gov/project_info_description.cfm?aid=8327725">THE EFFECT OF VAPORIZED CANNABIS ON NEUROPATHIC PAIN IN SPINAL CORD INJURY</a></td>
<td>Plant (cannabis, vaporized)</td>
<td>Human</td>
</tr>
</tbody>
</table>
<table class="full">
<caption><span class="title">Psychiatric Disorder</span></caption>
<thead>
<tr class="odd">
<th class="45" scope="col">Project Title</th>
<th class="35" scope="col">Cannabinoid</th>
<th class="30" scope="col">Study Model</th>
</tr>
</thead>
<thead></thead>
<tbody>
<tr class="odd">
<td scope="row"><a href="http://projectreporter.nih.gov/project_info_description.cfm?aid=8313866">CANNABIDIOL MODULATION OF ???-9-THC???S PSYCHOTOMIMETIC EFFECTS IN HEALTHY HUMANS</a></td>
<td>Purified (Cannabidiol)</td>
<td>Human</td>
</tr>
<tr class="even">
<td scope="row"><a href="http://projectreporter.nih.gov/project_info_description.cfm?aid=8632172">CANNABIS, SCHIZOPHRENIA AND REWARD: SELF-MEDICATION AND AGONIST TREATMENT?</a></td>
<td>Synthetic and Plant (Dronabinol &amp; cannabis cigarettes)</td>
<td>Human</td>
</tr>
</tbody>
</table>
<table class="full">
<caption><span class="title">Seizures</span></caption>
<tbody>
<tr class="odd">
<th class="45" scope="col">Project Title</th>
<th class="35" scope="col">Cannabinoid</th>
<th class="30" scope="col">Study Model</th>
</tr>
</tbody>
<tbody>
<tr class="odd">
<td scope="row"><a href="http://projectreporter.nih.gov/project_info_description.cfm?aid=7907545">NEW DRUGS TO ENHANCE ENDOCANNABINOID RESPONSES FOR TREATING EXCITOTOXICITY, PHASE</a></td>
<td>Endogenous (AE via FAAH inhibitors)</td>
<td>Animal</td>
</tr>
</tbody>
</table>
<table class="full">
<caption><span class="title">SUD, Withdrawal, and Dependence</span></caption>
<thead>
<tr class="odd">
<th class="45" scope="col">Project Title</th>
<th class="35" scope="col">Cannabinoid</th>
<th class="30" scope="col">Study Model</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td scope="row"><a href="http://projectreporter.nih.gov/project_info_description.cfm?aid=8473835">CANNABINERGIC MEDICATIONS FOR METHAMPHETAMINE ADDICTION</a></td>
<td>Synthetic (CB1 agonists and antagonists, proprietary)</td>
<td>Animal</td>
</tr>
<tr class="even">
<td scope="row"><a href="http://projectreporter.nih.gov/project_info_description.cfm?aid=8225155">EFFICACY AND SAFETY OF DRONABINOL (ORAL THC) FOR TREATING CANNABIS DEPENDENCE</a></td>
<td>Synthetic (Dronabinol)</td>
<td>Human</td>
</tr>
<tr class="odd">
<td scope="row"><a href="http://projectreporter.nih.gov/project_info_description.cfm?aid=8499512">EVALUATION OF NOVEL PHARMACOTHERAPIES FOR THE TREATMENT OF OPIOID DEPENDENCE</a></td>
<td>Synthetic (Dronabinol, Nabilone)</td>
<td>Human</td>
</tr>
<tr class="even">
<td scope="row"><a href="http://projectreporter.nih.gov/project_info_description.cfm?aid=8466946">FAAH-INHIBITOR FOR CANNABIS DEPENDENCE</a></td>
<td>Endogenous (AE via PF-04457845 FAAH inhibitor)</td>
<td>Human</td>
</tr>
<tr class="odd">
<td scope="row"><a href="http://projectreporter.nih.gov/project_info_description.cfm?aid=8473838">MARIJUANA RELAPSE: INFLUENCE OF TOBACCO CESSATION AND VARENICLINE</a></td>
<td>Sythetic (Dronabinol )+/- the noncannabinoid varenicline</td>
<td>Human</td>
</tr>
<tr class="even">
<td scope="row"><a href="http://projectreporter.nih.gov/project_info_description.cfm?aid=8505472">MEDICATIONS DEVELOPMENT FOR CANNABIS-USE DISORDERS: CLINICAL STUDIES</a></td>
<td>Purified (THC) and non-cannabinoids: Gabapentin &amp; Tiagabine</td>
<td>Human</td>
</tr>
<tr class="odd">
<td scope="row"><a href="http://projectreporter.nih.gov/project_info_description.cfm?aid=8507194">MONOACYLGLYCEROL LIPASE INHIBITORS FOR TREATING OPIOID USE DISORDERS</a> + supplement</td>
<td>Endogenous (2-AG via JZL184 MAGL inhibitor)</td>
<td>Animal</td>
</tr>
<tr class="even">
<td scope="row"><a href="http://projectreporter.nih.gov/project_info_description.cfm?aid=8656889">NABILONE FOR CANNABIS DEPENDENCE: IMAGING AND NEUROPSYCHOLOGICAL PERFORMANCE</a> + supplement</td>
<td>Synthetic (Nabilone)</td>
<td>Human</td>
</tr>
<tr class="odd">
<td scope="row"><a href="http://projectreporter.nih.gov/project_info_description.cfm?aid=8464038">NOVEL MEDICATION APPROACHES FOR SUBSTANCE ABUSE</a></td>
<td>Synthetic (Dronabinol, Project 4)+noncannabinoid lofexidine</td>
<td>Human</td>
</tr>
<tr class="even">
<td scope="row"><a href="http://projectreporter.nih.gov/project_info_description.cfm?aid=8477161">NOVEL MEDICATIONS FOR CANNABIS DEPENDENCE</a></td>
<td>Synthetic (Modify THC and nabilone to create new cannabinoids)</td>
<td>Animal</td>
</tr>
<tr class="odd">
<td scope="row"><a href="http://projectreporter.nih.gov/project_info_description.cfm?aid=8166445">SATIVEX ASSOCIATED WITH BEHAVIOURAL-PREVENTION RELAPSE STRATEGY AS TREATMENT FOR</a> + supplement</td>
<td>Purified (Sativex) +/- behavioral therapy</td>
<td>Human</td>
</tr>
<tr class="even">
<td scope="row"><a href="http://projectreporter.nih.gov/project_info_description.cfm?aid=8561004">STRESS-INDUCED MARIJUANA SELF-ADMINISTRATION: ROLE OF SEX AND OXYTOCIN</a></td>
<td>Plant (cannabis cigarettes)</td>
<td>Human</td>
</tr>
<tr class="odd">
<td scope="row"><a href="http://projectreporter.nih.gov/project_info_description.cfm?aid=8512680">TREATMENT OF CANNABINOID WITHDRAWAL IN RHESUS MONKEYS</a></td>
<td>Purified (THC) and Endogenous (via AEA via FAAH inhibitors)</td>
<td>Animal</td>
</tr>
</tbody>
</table>
<div class="textbox yellow"><a href="http://www.drugabuse.gov/drugs-abuse/marijuana/independently-funded-studies-receving-research-grade-marijuana-1999-to-present">Independently Funded Studies Receiving Research Grade Marijuana &#8211; 1999 to present</a></div>
<div class="textbox yellow"></div>
<div class="textbox yellow"></div>
<div class="textbox yellow"><a href="http://www.drugabuse.gov/drugs-abuse/marijuana/nida-research-therapeutic-benefits-cannabis-cannabinoids" target="_blank">Source Link</a></div>
]]></content:encoded>
					
					<wfw:commentRss>https://www.21delivery.com/nida-research-on-the-therapeutic-benefits-of-cannabis-and-cannabinoids/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
	</channel>
</rss>
